Life Sciences
Closing the Loop Between Research and Care.
New Frontier Life Sciences runs three platforms as a single continuum — clinical research, cell and gene therapy, and cross-border commercialization. Our hospitals are also our trial sites. Our trial sites are also our commercial launchpads.
The Footprint
A CRO Built Inside a Hospital Network.
Three things determine whether clinical research reaches patients quickly: an operator with skin in the game, a network deep enough to recruit, and a bridge to global markets. The numbers below describe what we operate ourselves, plus the partner network we extend through.
Owned Hospitals
Owned Clinics
Partner GCP Sites
Annual Outpatients
Medical Experts
The Premise
Research Only Matters When It Reaches a Patient.
Most clinical research platforms in China face one of two structural disadvantages. Academic centers offer deep clinical expertise but limited operational agility. Commercial CROs offer operational sophistication but no real clinical voice. We are neither.
We operate 32 hospitals and 32 clinics directly — including United Family Healthcare, Care Alliance, and YDCare — and extend through 200+ partnered GCP institutions, including the country's leading academic medical centers. The same buildings where care happens are also where research runs and where approved therapies first reach patients.
Three platforms, one operator
NF Nova for clinical research, NF CGT Platform for cell and gene therapy, NF Meditech for cross-border commercialization. All under unified governance.
Trial sites that are also launchpads
Approved products move from research to commercial use across the same network — without changing buildings, teams, or systems of record.
Decisions at clinical speed
Investigators and treating physicians sit at the same tables. Operational decisions don't queue at unaffiliated sites.
NF Nova · Clinical Research & CRO
A CRO Run by an Operating Healthcare Group.
NF Nova is the group's clinical research arm — a Contract Research Organization conducting Phase I–III, investigator-initiated, real-world evidence, decentralized, and bioequivalence trials. Studies run across both our owned hospitals and the country's leading partnered GCP institutions, including Peking Union Medical College Hospital and West China Hospital.
Sponsors get the operational discipline of a top-tier CRO and the clinical depth of an integrated healthcare group — without having to choose between them.
GCP regulatory trials
Phase I–III pharmaceutical and medical device trials conducted to China CDE standards across the full network.
Investigator-initiated and real-world evidence
Flexible IIT services and post-marketing data collection across 100,000+ accumulated patients.
Decentralized clinical trials
Our home-care network reaches patients directly, reducing patient burden and expanding recruitable populations to where patients already live.
AI-enabled operations
Trial setup, monitoring, and data review reshaped by automation. Clinical reporting time reduced from 30 minutes to under 6.
NF CGT Platform · Cell & Gene Therapy
Cell and Gene Therapy, Bench to Bedside.
Cell and gene therapy demands infrastructure most CROs simply don't have: dedicated cell-handling facilities, specialized clinical capacity, and regulatory pathways for the most complex therapeutic class in modern medicine.
We anchor our CGT work at Xiangya Boai Hospital — a Class-3A facility with full cell preparation and administration capacity. We extend it through Boao Lecheng in Hainan and the Beidaihe Life Sciences Park, two of China's specialized early-access pilot zones. And we partner with 50+ leading CGT developers, globally and domestically.
Class-3A anchor site
Xiangya Boai handles trial enrollment, cell preparation, and first-in-China administration directly — under our own clinical governance.
Pilot-zone access
Boao Lecheng and Beidaihe Life Sciences Park enable patient access well before standard mainland approval timelines.
50+ CGT partners
Strategic relationships with leading domestic and international developers, spanning oncology, rare disease, and inherited disorders.
Full lifecycle
From early-stage investment and translational work through clinical trials and commercial launch — under one operator.
NF Meditech · Cross-Border Commercialization
Chinese Innovation, Global Reach.
China's pharmaceutical and medical device sector now produces innovations the rest of the world increasingly wants access to. The bottleneck isn't the science — it's the regulatory, commercial, and logistical work of moving it across borders.
NF Meditech is our cross-border arm. Anchored in the Greater Bay Area and operating through Hong Kong's international regulatory environment, we move Chinese innovations outward and selected global therapies inward — with full regulatory, supply-chain, and patient-access support.
Hong Kong as international gateway
The regulatory and commercial environment that lets Chinese innovators reach global markets and gives global therapies a structured path into China.
International multi-center trials
Global clinical research programs managed from Hong Kong, with cross-border patient flow into the GBA network.
Designated Named Patient Programme
Inbound access for critical, life-changing treatments during the pre-approval window — for patients who cannot wait.
End-to-end commercialization
Regulatory strategy, multi-jurisdiction filings, cold-chain logistics, and distribution — coordinated as a single workstream.
Sponsor Onboarding
From Sponsor Inquiry to First Patient Enrolled.
A typical timeline for an investigator-initiated or industry-sponsored trial. Aggressive but realistic.
- 01
Initial scientific review
Within 10 business days, our scientific advisory team provides a structured response: site fit, projected enrollment, regulatory considerations, and budget framework.
- 02
Protocol finalization and contracting
Protocol amendments to optimize for our network operating realities, contract negotiation, and budget agreement — typically completed within 30 days.
- 03
Regulatory submission
IRB and regulatory submission handled by our in-house team. Average approval timeline of 45 to 60 days for standard trial designs.
- 04
Site activation and first patient enrolled
Once approved, sites are activated within 14 days. First patient enrollment averages 18 days from site activation across our network.
From Innovation Leadership
The faster a discovery becomes a treatment, the more people it can help. Our work is to compress that path — so more therapies reach more patients, in time to matter.
Wang Tao
Chief Executive Officer, NF Nova
Partner for Breakthroughs.
Whether you're advancing a CGT program, registering a novel device, or planning a cross-border launch, our platform is built to move at the speed of clinical work.